W Flanagan - Avidity Biosciences Chief Officer
| RNA Stock | USD 43.33 0.47 1.07% |
Executive
W Flanagan is Chief Officer of Avidity Biosciences
| Age | 61 |
| Address | 10578 Science Center Drive, San Diego, CA, United States, 92121 |
| Phone | 858 401 7900 |
| Web | https://www.aviditybiosciences.com |
Avidity Biosciences Management Efficiency
The company has Return on Asset of (0.1833) % which means that on every $100 spent on assets, it lost $0.1833. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.2776) %, meaning that it generated no profit with money invested by stockholders. Avidity Biosciences' management efficiency ratios could be used to measure how well Avidity Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of November 28, 2024, Return On Tangible Assets is expected to decline to -0.35. The current year's Return On Capital Employed is expected to grow to -0.41. At present, Avidity Biosciences' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 7.7 M, whereas Other Assets are forecasted to decline to 0.95.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Paul Graffagnino | IGM Biosciences | N/A | |
| Cindy Berejikian | Mineralys Therapeutics, Common | N/A | |
| Adam Dubow | Day One Biopharmaceuticals | 57 | |
| Patrick Lamy | Akero Therapeutics | 51 | |
| David Liu | Protagonist Therapeutics | 74 | |
| Mike JD | Pliant Therapeutics | 51 | |
| Xiaolin Wang | Revolution Medicines | 53 | |
| Jan Smith | Revolution Medicines | N/A | |
| TaiAn Lin | SpringWorks Therapeutics | N/A | |
| Matthew Gosling | Protagonist Therapeutics | 53 | |
| Prof MD | Day One Biopharmaceuticals | 55 | |
| Ronald Peck | Arvinas | N/A | |
| John Northcott | Arvinas | 46 | |
| Jason Hoitt | Stoke Therapeutics | 46 | |
| Carena Spivey | Protagonist Therapeutics | N/A | |
| John Grosso | Arvinas | 67 | |
| Asif Ali | Protagonist Therapeutics | 50 | |
| Matthew JD | Protagonist Therapeutics | 53 | |
| Kevin Johnston | Cullinan Oncology LLC | N/A | |
| Elly MD | Day One Biopharmaceuticals | N/A | |
| Scott Gangloff | Akero Therapeutics | 50 | |
Management Performance
| Return On Equity | -0.28 | ||||
| Return On Asset | -0.18 |
Avidity Biosciences Leadership Team
Elected by the shareholders, the Avidity Biosciences' board of directors comprises two types of representatives: Avidity Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Avidity. The board's role is to monitor Avidity Biosciences' management team and ensure that shareholders' interests are well served. Avidity Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Avidity Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kathleen Gallagher, Sr Relations | ||
| Teresa McCarthy, Chief Officer | ||
| Eric Mosbrooker, Chief Officer | ||
| Sarah Boyce, CEO President | ||
| III JD, Consultant | ||
| Michael CPA, Chief Officer | ||
| Michael MacLean, Chief Officer | ||
| Prof Davis, Member Founder | ||
| Moriarty ESQ, Chief Secretary | ||
| Arthur Levin, Strategic Scientist | ||
| John III, General Property | ||
| Troy JD, CoFounder Chairman | ||
| Frank McCormick, Scientific Board | ||
| W Flanagan, Chief Officer | ||
| Michael Flanagan, Chief Officer | ||
| Geoffrey CFA, VP Communication |
Avidity Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Avidity Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.28 | ||||
| Return On Asset | -0.18 | ||||
| Operating Margin | (42.01) % | ||||
| Current Valuation | 3.59 B | ||||
| Shares Outstanding | 119.31 M | ||||
| Shares Owned By Insiders | 4.82 % | ||||
| Shares Owned By Institutions | 95.18 % | ||||
| Number Of Shares Shorted | 14.52 M | ||||
| Price To Earning | (12.91) X | ||||
| Price To Book | 3.44 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Avidity Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Avidity Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Avidity Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Avidity Biosciences Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Avidity Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Avidity Stock refer to our How to Trade Avidity Stock guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avidity Biosciences. If investors know Avidity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avidity Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.88) | Revenue Per Share 0.103 | Quarterly Revenue Growth (0.17) | Return On Assets (0.18) | Return On Equity (0.28) |
The market value of Avidity Biosciences is measured differently than its book value, which is the value of Avidity that is recorded on the company's balance sheet. Investors also form their own opinion of Avidity Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Avidity Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avidity Biosciences' market value can be influenced by many factors that don't directly affect Avidity Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avidity Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avidity Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avidity Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.